

[Etoposide](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01CB01](#)

EMLc

Indication

Ewing sarcoma of bone and articular cartilage of unspecified sites ICD11 code: [2C22.Z](#)

INN

Etoposide

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule ; 100 mg in vial powder for injection (as phosphate)

Oral > Solid: 100 mg capsule ; 50 mg capsule

EML status history

First added in 2015 ([TRS 994](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Etoposide](#)

DrugBank

[Etoposide](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of etoposide (Powder for injection: 100 mg (as phosphate) in vial) to the EML and EMLc.